Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis

K Papp, H Bachelez, A Costanzo, P Foley, M Gooderham, P Kaur, S Philipp, L Spelman, N Zhang, B Strober

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis'. Together they form a unique fingerprint.

Medicine & Life Sciences